Purpose. Hypertension is a common adverse effect of vascular endothelial growth factor (VEGF) signaling inhibitors, such as bevacizumab, with an incidence upwards of 35%. The management of bevacizumab-induced hypertension is important in order to avoid dose interruption/discontinuation and/or end organ damage. The efficacy of antihypertensive medications for this cause of hypertension has not been demonstrated. This study seeks to determine if antihypertensives are effective in treating anti-VEGF-induced hypertension from bevacizumab and determine which classes of antihypertensive agents are effective.
Methods. A retrospective review of all patients who received bevacizumab between January 2007 and September 2009 at two medical centers was conducted. Patients were included if they experienced new onset or exacerbation of preexisting hypertension, during bevacizumab treatment. Efficacy of antihypertensives was determined by recording a 28-day change in systolic blood pressure from the initiation or dose increase of individual antihypertensive medications. Secondary endpoints included an efficacy analysis of antihypertensive classes.
Results. Five-hundred thirteen patients were identified as receiving bevacizumab during the indicated time period. Fifty-seven patients met the full inclusion/exclusion criteria for analysis. The average systolic blood pressure declined by 23 mm Hg with 4 weeks of treatment (p < 0.0001). Each class had a statistically significant decline in systolic blood pressure of 15.5–57 mm Hg with the exception of diuretics and a group of miscellaneous antihypertensives.
Conclusions. This is the first data that demonstrates individual classes of antihypertensives are effective in bevacizumab-induced hypertension. Most antihypertensives were effective in reducing blood pressure, with the exception of diuretics and miscellaneous antihypertensives, which may be due to a limited sample size.
ScolnikP.mAbs, A business perspective. mAbs2009; 1(2): 179–184.
3.
ShordSSBresslerLRTierneyLACuellarSGeorgeA.Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm2009; 66(11): 999–1013.
4.
YangJCHaworthLSherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003; 349(5): 427–434.
5.
GressettSMShahSR.Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother2009; 43(3): 490–501.
6.
PouesselDCulineS.High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol2008; 53(2): 376–381.
7.
IzzedineHEderhySGoldwasserF. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol2009; 20(5): 807–815.
8.
GurevichFPerazellaMA.Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med2009; 122(4): 322–328.
9.
HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004; 350(23): 2335–2342.
10.
ChobanianAVBakrisGLBlackHR. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA2003; 289(19): 2560–2572.
11.
PoolJLKaihlanenPLewisGROparilSGlazerRMesserliFH.Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hyperten2001; 15: 495–498.
12.
PhilippTSmithSRGlazerRWernsingMYenJJinJ.Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Therap2007; 29(4): 563–580.
LangenbergMHvan HerpenCMDe BonoJSchellensJHUngerCHoekmanK.Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase ii randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol2009; 27(36): 6152–6159.
15.
MiuraSFujinoMMatsuoYTanigawaHSakuK.Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes enodthelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res2005; 28(2): 147–153.
16.
SiddiquiAJMansson-BrobergAGustafssonTGrinnemoKHDellgreenGHaoX.Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens2005; 18(10): 1347–1352.
17.
KosugiMMiyajimaAKikuchiEHoriguchiYMuraiM.Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res2006; 12(9): 2888–2893.
